PJB-2025-19
Anti-inflammatory and anti-platelet aggregation activity of silibinin-encapsulated hydrogel against rheumatoid arthritis in rat model
Quindeel naveed
Abstract
Background: Rheumatoid arthritis (RA) is a systematic auto-immune disorder which is characterized by the inflammation in joints resulting into swelling, stiffness and pain. Platelet aggregation is a leading cause of thrombotic and cardiovascular-risk events that are associated with the usage of celecoxib; a currently available drug for the RA-treatment. Silibinin (SB) as an active component of Silybum marianum has been reported for its anti-inflammatory activity. Hydrogels being characterized as the targeted drug-delivery-systems offer promising therapeutic effects in terms of an enhanced and a controlled drug-release. Objectives: This research study is designed to investigate the cyclooxygenase-2 (COX-2) inhibitory activity of silibinin containing hydrogels along with their potential anti-platelet aggregation activity. Methods: Silibinin containing chitosan-glycerol-borax hydrogels were prepared using the process of magnetic-stirring and were injected into the collagen-type-II induced arthritis in rat model. The COX-2 inhibitory activity of silibinin containing hydrogels was measured using a rat-(prostaglandin-endo-peroxidase-synthase-2)-ELISA-kit, and, the platelets aggregation was measured using an optical-chronolog aggregatometer. Results: A significant decrease in the levels of COX-2 as well as the platelet aggregation was observed for the administration of silibinin-containing-hydrogels. A p-value of less than 0.01 was observed when the results were analyzed. Conclusion: Silibinin was seen to be exhibiting an effective COX-2 inhibitory-activity in comparison to celecoxib, along with reducing the side effects of celecoxib in terms of inhibiting the platelet aggregation caused by celecoxib. Thus, on the basis of its enhanced anti-inflammatory and the anti-platelet-aggregation activity, silibinin may serve as an effective therapeutic-agent for the treatment of RA.